Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Other Working Capital Changes (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Other Working Capital Changes for 12 consecutive years, with -$2.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Working Capital Changes fell 127.52% to -$2.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$10.9 million, a 615.85% decrease, with the full-year FY2025 number at -$10.9 million, down 615.85% from a year prior.
  • Other Working Capital Changes was -$2.9 million for Q4 2025 at Iovance Biotherapeutics, down from -$2.4 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $10.5 million in Q4 2024 to a low of -$8.8 million in Q2 2025.
  • A 3-year average of $106250.0 and a median of -$2.3 million in 2023 define the central range for Other Working Capital Changes.
  • Biggest YoY gain for Other Working Capital Changes was 155.21% in 2025; the steepest drop was 2256.34% in 2025.
  • Iovance Biotherapeutics' Other Working Capital Changes stood at $5.1 million in 2023, then soared by 104.66% to $10.5 million in 2024, then tumbled by 127.52% to -$2.9 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Other Working Capital Changes are -$2.9 million (Q4 2025), -$2.4 million (Q3 2025), and -$8.8 million (Q2 2025).